Northern Trust Corp Has $21.23 Million Holdings in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

Northern Trust Corp decreased its position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) by 28.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 445,091 shares of the company’s stock after selling 178,790 shares during the quarter. Northern Trust Corp owned 0.90% of Turning Point Therapeutics worth $21,231,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Lindbrook Capital LLC bought a new position in shares of Turning Point Therapeutics during the fourth quarter worth about $49,000. Squarepoint Ops LLC bought a new position in shares of Turning Point Therapeutics during the 3rd quarter worth approximately $210,000. Franklin Resources Inc. acquired a new stake in shares of Turning Point Therapeutics in the third quarter valued at approximately $219,000. Janus Henderson Group PLC bought a new stake in shares of Turning Point Therapeutics in the third quarter worth $275,000. Finally, Envestnet Asset Management Inc. boosted its holdings in Turning Point Therapeutics by 39.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 5,106 shares of the company’s stock worth $244,000 after purchasing an additional 1,443 shares during the last quarter. Institutional investors own 90.33% of the company’s stock.

Shares of TPTX stock opened at $32.60 on Friday. Turning Point Therapeutics, Inc. has a 52 week low of $23.77 and a 52 week high of $83.06. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of -5.86 and a beta of 0.86. The company has a 50-day simple moving average of $28.96 and a 200 day simple moving average of $35.84.

Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($1.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.01. The firm had revenue of $0.40 million for the quarter. The company’s revenue for the quarter was down 98.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.73) EPS. As a group, equities research analysts anticipate that Turning Point Therapeutics, Inc. will post -6.74 earnings per share for the current fiscal year.

Several equities research analysts have commented on the stock. Wedbush cut their price target on shares of Turning Point Therapeutics from $93.00 to $61.00 in a research report on Wednesday. Stifel Nicolaus dropped their target price on Turning Point Therapeutics from $50.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, March 1st. HC Wainwright decreased their price target on Turning Point Therapeutics from $162.00 to $161.00 and set a “buy” rating for the company in a research note on Tuesday, March 22nd. Wells Fargo & Company decreased their target price on shares of Turning Point Therapeutics from $120.00 to $85.00 and set an “overweight” rating for the company in a research note on Thursday, February 10th. Finally, Zacks Investment Research upgraded shares of Turning Point Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Turning Point Therapeutics has an average rating of “Buy” and a consensus target price of $86.86.

About Turning Point Therapeutics (Get Rating)

Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

See Also